BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 15725082)

  • 1. Low-grade primary central nervous system lymphoma in immunocompetent patients.
    Jahnke K; Thiel E; Schilling A; Herrlinger U; Weller M; Coupland SE; Krümpelmann U; Stein H; Korfel A
    Br J Haematol; 2005 Mar; 128(5):616-24. PubMed ID: 15725082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
    Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
    Pöttgen C; Stuschke M; Stüben G; Schmitz A; Schwechheimer K; Wacker HH; Rauhut F; Kleuker S; Wilhelm H; Grehl S; Fehlings T
    Strahlenther Onkol; 2003 Sep; 179(9):626-32. PubMed ID: 14628129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary central nervous system lymphoma: a profile of 26 cases from Western India.
    Agarwal PA; Menon S; Smruti BK; Singhal BS
    Neurol India; 2009; 57(6):756-63. PubMed ID: 20139505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of combined-modality therapy for primary and secondary malignant lymphoma of the central nervous system (CNS).
    Kawamura T; Koga S; Okamoto M; Kanno T; Iwamura H
    Radiat Med; 2001; 19(3):145-9. PubMed ID: 11467381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
    Shenkier TN; Voss N; Chhanabhai M; Fairey R; Gascoyne RD; Hoskins P; Klasa R; Morris J; O'Reilly SE; Pickles T; Sehn L; Connors JM
    Cancer; 2005 Mar; 103(5):1008-17. PubMed ID: 15651059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International study on low-grade primary central nervous system lymphoma.
    Jahnke K; Korfel A; O'Neill BP; Blay JY; Abrey LE; Martus P; Poortmans PM; Shenkier TN; Batchelor TT; Neuwelt EA; Raizer JJ; Schiff D; Pels H; Herrlinger U; Stein H; Thiel E
    Ann Neurol; 2006 May; 59(5):755-62. PubMed ID: 16586496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003 : time trends in a 15-year national survey.
    Haldorsen IS; Krossnes BK; Aarseth JH; Scheie D; Johannesen TB; Mella O; Espeland A
    Cancer; 2007 Oct; 110(8):1803-14. PubMed ID: 17721992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary central nervous system non-Hodgkin's lymphoma (PCNSL): does age and histology at presentation affect outcome?
    Schaller C; Kelly PJ
    Zentralbl Neurochir; 1996; 57(3):156-62. PubMed ID: 8794548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary CNS lymphoma treated with combined intra-arterial ACNU and radiotherapy.
    Sonoda Y; Matsumoto K; Kakuto Y; Nishino Y; Kumabe T; Tominaga T; Katakura R
    Acta Neurochir (Wien); 2007 Nov; 149(11):1183-9; discussion 1189. PubMed ID: 17712511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary central nervous system lymphomas: a 30-year experience at a single institution.
    Nuckols JD; Liu K; Burchette JL; McLendon RE; Traweek ST
    Mod Pathol; 1999 Dec; 12(12):1167-73. PubMed ID: 10619271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Primary cerebral non-Hodgkin's lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the registry of non-Hodgkin's lymphoma in western Denmark, LYFO and the cancer registry, Kraeftens Bekaempelse].
    Jensen MK; d'Amore FA; Jensen MK; Christensen BE; Thorling K; Pedersen M; Johansen P; Boesen AM; Andersen E
    Ugeskr Laeger; 1996 Jul; 158(31):4406-12. PubMed ID: 8759999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [T-type primary lymphoma of the central nervous system in immunocompetent patients].
    Barrena-Caballo MR; Blanch-Labrador M; Giménez-Mas JA; Alberdi-Viñas J; Pascual-Piazuelo M; Zubiri-Ara L
    Rev Neurol; 2003 Jan 16-31; 36(2):125-30. PubMed ID: 12589598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary central nervous system lymphoma.
    Ferreri AJ; Reni M
    Crit Rev Oncol Hematol; 2007 Sep; 63(3):257-68. PubMed ID: 17590348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
    Korfel A; Martus P; Nowrousian MR; Hossfeld DK; Kirchen H; Brücher J; Stelljes M; Birkmann J; Peschel C; Pasold R; Fischer L; Jahnke K; Thiel E;
    Br J Haematol; 2005 Jan; 128(2):177-83. PubMed ID: 15638851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
    Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, clinical features, treatment and outcome of primary central nervous system lymphoma in Norway.
    Salvesen Haldorsen I; Aarseth JH; Hollender A; Larsen JL; Espeland A; Mella O
    Acta Oncol; 2004; 43(6):520-9. PubMed ID: 15370608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
    Colombat P; Lemevel A; Bertrand P; Delwail V; Rachieru P; Brion A; Berthou C; Bay JO; Delepine R; Desablens B; Camilleri-Broët S; Linassier C; Lamy T
    Bone Marrow Transplant; 2006 Sep; 38(6):417-20. PubMed ID: 16951691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for central nervous system lymphomas in immunocompetent patients.
    Jahnke K; Thiel E
    Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.